Drug Target Identification Using Side-Effect Similarity
Open accessThe DOI matches its Crossref record; 26 of the 27 references it cites were found in a registry or an index.
Abstract
Targets for drugs have so far been predicted on the basis of molecular or cellular features, for example, by exploiting similarity in chemical structure or in activity across cell lines. We used phenotypic side-effect similarities to infer whether two drugs share a target. Applied to 746 marketed drugs, a network of 1018 side effect–driven drug-drug relations became apparent, 261 of which are formed by chemically dissimilar drugs from different therapeutic indications. We experimentally tested 20 of these unexpected drug-drug relations and validated 13 implied drug-target relations by in vitro binding assays, of which 11 reveal inhibition constants equal to less than 10 micromolar. Nine of these were tested and confirmed in cell assays, documenting the feasibility of using phenotypic information to infer molecular interactions and hinting at new uses of marketed drugs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The work of Campillios et al. previously suggested the similarity of two drugs’ side effect profiles is positively correlated with the probability that these drugs share a common target28.”
From OnSIDES database: Extracting adverse drug events from drug labels using natural language processing models (2025) · cites this paper as [28]
Citations
Cites
The unified medical language system (UMLS): integrating biomedical terminology
Bodenreider, O. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh061 · Cited by 4,356
Docking and scoring in virtual screening for drug discovery: methods and applications
Kitchen, D. B., Decornez, H., Furr, J. R., & Bajorath, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1549 · Cited by 4,150
DrugBank: a comprehensive resource for in silico drug discovery and exploration
Wishart, D. S. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkj067 · Cited by 3,892
Drug repositioning: identifying and developing new uses for existing drugs
Ashburn, T. T., & Thor, K. B. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1468 · Cited by 3,237
Relating protein pharmacology by ligand chemistry
Keiser, M. J., Roth, B. L., Armbruster, B. N., Ernsberger, P., Irwin, J. J., & Shoichet, B. K. (2007) · Nature Biotechnology · doi:10.1038/nbt1284 · Cited by 2,402
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
Tsai, J., Lee, J. T., Wang, W., Zhang, J., Cho, H., Mamo, S., Bremer, R., Gillette, S., Kong, J., Haass, N. K., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711741105 · Cited by 1,346
Gohlke, H., & Klebe, G. (2002) · Angewandte Chemie International Edition · doi:10.1002/1521-3773(20020802)41:15<2644::aid-anie2644>3.0.co;2-o · Cited by 843
Global mapping of pharmacological space
Paolini, G. V., Shapland, R. H. B., van Hoorn, W. P., Mason, J. S., & Hopkins, A. L. (2006) · Nature Biotechnology · doi:10.1038/nbt1228 · Cited by 811
Do Structurally Similar Molecules Have Similar Biological Activity?
Martin, Y. C., Kofron, J. L., & Traphagen, L. M. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020155c · Cited by 806
SuperTarget and Matador: resources for exploring drug-target relationships
Gunther, S., Kuhn, M., Dunkel, M., Campillos, M., Senger, C., Petsalaki, E., Ahmed, J., Urdiales, E. G., Gewiess, A., Jensen, L. J., et al. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm862 · Cited by 647
Self-citation
Research works printed but not linked: 3
- J. Blagg, Annu. Rep. Med. Chem.41, 353 (2006).
- S. Guntheret al., Nucleic Acids Res.36, D919 (2008).
- C. M. Krejsaet al., Curr. Opin. Drug Discov. Dev.6, 470 (2003).
Cited by
Items 501–600 of 1,000
Transcriptomic Data Mining and Repurposing for Computational Drug Discovery
Wang, Y., Yella, J., & Jegga, A. G. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8955-3_5 · Cited by 38
Multi-channel PINN: investigating scalable and transferable neural networks for drug discovery
Lee, M., Kim, H., Joe, H., & Kim, H. (2019) · Journal of Cheminformatics · doi:10.1186/s13321-019-0368-1 · Cited by 35
Detecting Drug Promiscuity Using Gaussian Ensemble Screening
Pérez‐Nueno, V. I., Venkatraman, V., Mavridis, L., & Ritchie, D. W. (2012) · Journal of Chemical Information and Modeling · doi:10.1021/ci3000979 · Cited by 34
Predicting drug targets based on protein domains
Wang, Y., Nacher, J. C., & Zhao, X.-M. (2012) · Molecular BioSystems · doi:10.1039/c2mb05450g · Cited by 32
Jin, L., Tu, J., Jia, J., An, W., Tan, H., Cui, Q., & Li, Z. (2014) · Journal of Translational Medicine · doi:10.1186/1479-5876-12-153 · Cited by 35
“[4], molecular activity similarity [5], and shared molecular pathology [6].”
BackgroundWang, C., & Kurgan, L. (2018) · Briefings in Bioinformatics · doi:10.1093/bib/bby069 · Cited by 33
“This type of validation was done for the earliest predictor [112], the method that first defined DPS [114], and in one recent study [107].”
BackgroundMethodInfluentialDrug target inference through pathway analysis of genomics data
Ma, H., & Zhao, H. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.12.004 · Cited by 34
“Other phenotype information such as cell imaging and side effects have also been utilized to associate different drugs and to make inference about their potential targets [21,35].”
Computational systems approach for drug target discovery
Chandra, N. R. (2009) · Expert Opinion on Drug Discovery · doi:10.1517/17460440903380422 · Cited by 33
“Using a phenotypic drug adverse-effect profile, targets shared by a drug have been inferred and some experimentally validated [81] , making it important to construct and analyze drug–target networks to obtain a systems view of drug effects [14,82-84] .”
BackgroundSolving the Problem of New UsesPreprint
Roin, B. N. (2013) · SSRN Electronic Journal · doi:10.2139/ssrn.2337821 · Cited by 37
Zheng, Y., Ma, Y., Xiong, Q., Zhu, K., Weng, N., & Zhu, Q. X. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107381 · Cited by 34
In silico re-identification of properties of drug target proteins
Kim, B., Jo, J., Han, J., Park, C., & Lee, H. (2017) · BMC Bioinformatics · doi:10.1186/s12859-017-1639-3 · Cited by 38
“Recently, more resources, including side effects of drugs, drug-drug interactions, and protein-protein interactions, have been incorporated for predicting new drug targets [3, 4].”
BackgroundRealizing drug repositioning by adapting a recommendation system to handle the process
Özsoy, M. G., Özyer, T., Polat, F., & Alhajj, R. (2018) · BMC Bioinformatics · doi:10.1186/s12859-018-2142-1 · Cited by 36
“The works described in [1, 40] use side-effect similarity of drugs for drug repositioning.”
BackgroundIn Silico Drug Design Methods for Drug Repurposing
Akhoon, B. A., Tiwari, H., & Nargotra, A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816125-8.00003-1 · Cited by 37
IntSide: a web server for the chemical and biological examination of drug side effects
Juan-Blanco, T., Duran‐Frigola, M., & Aloy, P. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu688 · Cited by 33
Sharp, M. (2017) · Journal of Biomedical Semantics · doi:10.1186/s13326-016-0110-0 · Cited by 35
“Pioneering reports on ontology-based, in silico drug discovery have emerged [11 – 13].”
BackgroundHameed, P. N., Verspoor, K. M., Kusljic, S., & Halgamuge, S. K. (2018) · BMC Bioinformatics · doi:10.1186/s12859-018-2123-4 · Cited by 35
“[18] demonstrated the significance of using side effect similarity for drug repositioning.”
BackgroundInfluentialComputational methods for early predictive safety assessment from biological and chemical data
Nigsch, F., Lounkine, E., McCarren, P. R., Cornett, B., Glick, M., Azzaoui, K., Urbán, L., Marc, P., Müller, A., Hahne, F., et al. (2011) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2011.632632 · Cited by 32
“However, the successful alignment of chemical features [82,85] , as well as in vitro target-binding profiles [83,84] and gene expression data [73] with adverse reactions, has made it possible to express complex adverse events in terms of biological pathways and targets [86-89] .”
BackgroundMethodCurrent status and future prospects of drug–target interaction prediction
Ru, X., Ye, X., Sakurai, T., Zou, Q., Xu, L., & Lin, C. (2021) · Briefings in Functional Genomics · doi:10.1093/bfgp/elab031 · Cited by 30
“Although this phenomenon is not expected by researchers, it has been proved that off-target drugs can produce unexpected new therapeutic effects [11].”
BackgroundAn ensemble approach for drug side effect prediction
Jahid, M. J., & Ruan, J. (2013) · IEEE International Conference on Bioinformatics and Biomedicine (BIBM) · doi:10.1109/bibm.2013.6732532 · Cited by 33
Cao, D., Zhou, G., Liu, S., Zhang, L., Xu, Q., He, M., & Liang, Y. (2013) · Analytica Chimica Acta · doi:10.1016/j.aca.2013.07.003 · Cited by 37
Shape-Based Reprofiling of FDA-Approved Drugs for the H1 Histamine Receptor
Vasudevan, S. R., Moore, J. B., Schymura, Y., & Churchill, G. C. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300671m · Cited by 32
Haddad, Y., Adam, V., & Heger, Z. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00130 · Cited by 31
“A proNGF/sortilin/p75NTR ternary complex has also been reported (Feng et al., 2010).”
BackgroundThe role of computational methods in the identification of bioactive compounds
Glick, M., & Jacoby, E. (2011) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2011.02.021 · Cited by 34
From off-label prescribing towards a new FDA
Tabarrok, A. T. (2008) · Medical Hypotheses · doi:10.1016/j.mehy.2008.08.009 · Cited by 30
Machine learning with biomedical ontologiesPreprint
Kulmanov, M., Smaili, F. Z., Gao, X., & Hoehndorf, R. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.05.07.082164 · Cited by 35
Inferring protein domains associated with drug side effects based on drug-target interaction network
Iwata, H., Mizutani, S., Tabei, Y., Kotera, M., Goto, S., & Yamanishi, Y. (2013) · BMC Systems Biology · doi:10.1186/1752-0509-7-s6-s18 · Cited by 31
“In contrast, the key idea of the pharmacogenomic approach is that phenotypically similar drugs are likely to interact with similar proteins, and the prediction is performed based on drug side effects and/or protein sequences [8-10].”
BackgroundHeterogeneous network embedding enabling accurate disease association predictions
Xiong, Y., Guo, M., Ruan, L., Kong, X., Tang, C., Zhu, Y., & Wang, W. W. (2019) · BMC Medical Genomics · doi:10.1186/s12920-019-0623-3 · Cited by 31
Al-Taie, Z., Liu, D., Mitchem, J. B., Papageorgiou, C., Kaifi, J. T., Warren, W. C., & Shyu, C. (2021) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2021.103792 · Cited by 32
Gallina, A. M., Bork, P., & Bordo, D. (2014) · Journal of Molecular Recognition · doi:10.1002/jmr.2332 · Cited by 29
“In some instances, however, spurious cross-reactivity may reveal alternative andnew therapeutic possibilities for commercializeddrugs (Campillos et al., 2008), in particular for orphan diseases (Ekins et al., 2011; Sardana et al., 2011; Dakshanamurthy et al., 2012).”
BackgroundSelf-citationTargeting molecular networks for drug research
Pinto, J., Machado, R. S. R., Xavier, J. M., & Futschik, M. E. (2014) · Frontiers in Genetics · doi:10.3389/fgene.2014.00160 · Cited by 33
Translational Bioinformatics Approaches to Drug Development
Readhead, B., & Dudley, J. T. (2013) · Advances in Wound Care · doi:10.1089/wound.2012.0422 · Cited by 31
“On the assumption that such side effect profiles provide a read-out of the physiological effect of a compound on a host system, Campillos et al.(45) mapped medication side-effects from package leaflets, and mapped the listed terms to the Unified Medical Language System, creating weighted associations between side effe…”
BackgroundiFad: an integrative factor analysis model for drug-pathway association inference†
Ma, H., & Zhao, H. (2012) · Bioinformatics · doi:10.1093/bioinformatics/bts285 · Cited by 29
Scaffold Repurposing of Old Drugs Towards New Cancer Drug Discovery
Chen, H., Wu, J., Gao, Y., Chen, H., & Zhou, J. (2016) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026616666160216155556 · Cited by 31
Pharmacotherapy in Secondary Progressive Multiple Sclerosis: An Overview
Angelis, F. D., Plantone, D., & Chataway, J. (2018) · CNS Drugs · doi:10.1007/s40263-018-0538-0 · Cited by 32
A Drug-Side Effect Context-Sensitive Network approach for drug target prediction
Zhou, M., Chen, Y., & Xu, R. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty906 · Cited by 36
“The correlation weight gi of each SE was calculated by first hierarchal cluster all the SEs then weighted each SE based on the clustering using Gerstein-Sonnhammer-Chothia algorithm(Campillos et al., 2008).”
BackgroundMethodInfluentialA NOVEL MULTI-MODAL DRUG REPURPOSING APPROACH FOR IDENTIFICATION OF POTENT ACK1 INHIBITORS
Phatak, S. S., & Zhang, S. (2012) · Pacific Symposium on Biocomputing (PSB) · doi:10.1142/9789814447973_0004 · Cited by 32
Determining the mode of action of bioactive compounds
Azad, M. A., & Wright, G. D. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.10.088 · Cited by 33
Debnath, K., Rana, P., & Ghosh, P. (2025) · Briefings in Bioinformatics · doi:10.1093/bib/bbaf491 · Cited by 34
“Campillos et al. [15] utilized phenotypic side-effect similarities to infer potential shared targets between two drugs, discovering novel DTIs.”
A chemo-centric view of human health and disease
Duran‐Frigola, M., Rossell, D., & Aloy, P. (2014) · Nature Communications · doi:10.1038/ncomms6676 · Cited by 29
Comparing Drug Images and Repurposing Drugs with BioGPS and FLAPdock: The Thymidylate Synthase Case
Siragusa, L., Luciani, R., Borsari, C., Ferrari, S., Costi, M. P., Cruciani, G., & Spyrakis, F. (2016) · ChemMedChem · doi:10.1002/cmdc.201600121 · Cited by 28
Predicting Drug Targets from Heterogeneous Spaces using Anchor Graph Hashing and Ensemble Learning
Zheng, Y., Peng, H., Zhang, X., Gao, X., & Li, J. (2018) · International Joint Conference on Neural Networks (IJCNN) · doi:10.1109/ijcnn.2018.8489028 · Cited by 29
“The prediction is performed based on information such as drug chemical structures [5] [6], drug side-effects [7], target protein sequences [8], and the known drug-target interactions.”
BackgroundDrug repurposing with network reinforcement
Nam, Y., Kim, M.-J., Chang, H., & Shin, H. (2019) · BMC Bioinformatics · doi:10.1186/s12859-019-2858-6 · Cited by 28
Hinnerichs, T., & Hoehndorf, R. (2021) · Bioinformatics · doi:10.1093/bioinformatics/btab548 · Cited by 26
“Top-down methods use information about physiological effects of drugs for DTI prediction, such as side-effect similarity (Campillos et al., 2008), that is largely complementary to knowledge”
MethodPredicting cancer drug mechanisms of action using molecular network signatures
Pritchard, J. R., Bruno, P. M., Hemann, M. T., & Lauffenburger, D. A. (2012) · Molecular BioSystems · doi:10.1039/c2mb25459j · Cited by 30
A Strategy Based on Protein–Protein Interface Motifs May Help in Identifying Drug Off-Targets
Engin, H. B., Keskin, Ö., Nussinov, R., & Gürsoy, A. (2012) · Journal of Chemical Information and Modeling · doi:10.1021/ci300072q · Cited by 28
A Computational Approach to Analyze the Mechanism of Action of the Kinase Inhibitor Bafetinib
Burkard, T. R., Rix, U., Breitwieser, F. P., Superti‐Furga, G., & Colinge, J. (2010) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1001001 · Cited by 28
“potential side effects [6–11].”
Identifying Tinnitus‐Related Genes Based on a Side‐Effect Network Analysis
Elgoyhen, A. B., Langguth, B., Nowak, W., Schecklmann, M., Ridder, D. D., & Vanneste, S. (2014) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1038/psp.2013.75 · Cited by 30
Combinations of Protein-Chemical Complex Structures Reveal New Targets for Established Drugs
Kalinina, O. V., Wichmann, O., Apic, G., & Russell, R. B. (2011) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002043 · Cited by 29
“[3,5]) though to our knowledge this is the first attempt to use 3D structures in the network context in this way to link disparate chemicals and targets.”
BackgroundConcept-Based Semi-Automatic Classification of Drugs
Gurulingappa, H., Kolářik, C., Hofmann‐Apitius, M., & Fluck, J. (2009) · Journal of Chemical Information and Modeling · doi:10.1021/ci9000844 · Cited by 28
Dovrolis, N., Kolios, G. C., Spyrou, G. M., & Maroulakou, I. G. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.03.009 · Cited by 31
Matrine Is Identified as a Novel Macropinocytosis Inducer by a Network Target Approach
Zhang, B., Wang, X., Li, Y., Wu, M. H., Wang, S., & Li, S. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00010 · Cited by 35
“In recent years, many computational methods and algorithms have been developed to predict target profiles, such as phenotypic effect-based (Parsons et al., 2004; Campillos et al., 2008) and chemical structure-based approaches (Keiser et al., 2009).”
MethodMora, A., & Donaldson, I. M. (2012) · BMC Bioinformatics · doi:10.1186/1471-2105-13-294 · Cited by 30
“Bioinformatics methods to characterize and predict drug targets have included: pathway and tissue enrichment, domain enrichment, number of exons and protein degree in an interaction network [2], GO enrichment [3], sequence similarity to known targets [4], sideeffect similarity [5], physicochemical properties of the se…”
MethodWang, R., & Loscalzo, J. (2016) · Molecular BioSystems · doi:10.1039/c6mb00052e · Cited by 29
Müller, M., Georgiev, T., Mock, J., Neri, D., Cazzamalli, S., & Oehler, S. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c05198 · Cited by 27
A nonmainstream approach against cancer
Fais, S. (2016) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.3109/14756366.2016.1156105 · Cited by 27
“J Enzyme Inhib Med Chem, 2016; 31(6): 882–889”
Blucher, A., McWeeney, S. K., Stein, L. D., & Wu, G. (2019) · F1000Research · doi:10.12688/f1000research.19592.1 · Cited by 30
Overcoming Drug Resistance in Advanced Prostate Cancer by Drug Repurposing
Bahmad, H. F., Demus, T., Moubarak, M. M., Daher, D., Moreno, J. C. A., Polit, F., López, O., Merhe, A., Abou-Kheir, W. G., Nieder, A. M., et al. (2022) · Medical Sciences · doi:10.3390/medsci10010015 · Cited by 33
“Similar side effects between two different drugs are considered to indicate shared physiology, suggesting that they may have a similar mode of action by affecting the same target or pathway [91].”
BackgroundDrug Repositioning Using In Silico Compound Profiling
Dubus, E., Ijjaali, I., Barberan, O., & Petitet, F. (2009) · Future Medicinal Chemistry · doi:10.4155/fmc.09.123 · Cited by 28
García‐Sosa, A. T., Sild, S., Takkis, K., & Maran, U. (2011) · Journal of Chemical Information and Modeling · doi:10.1021/ci200203h · Cited by 29
Kissa, M., Tsatsaronis, G., & Schroeder, M. (2014) · Methods · doi:10.1016/j.ymeth.2014.11.017 · Cited by 27
Sethi, G., Chopra, G., & Samudrala, R. (2015) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557515666150219145148 · Cited by 27
“Examples include ranking gene expression profiles to explore drug repositioning opportunities [20-22], and mining existing drug side effects information to deduce novel drugtarget relationships to identify novel uses of existing drugs [23-24], among many others.”
BackgroundA novel algorithm for analyzing drug-drug interactions from MEDLINE literature
Lu, Y., Shen, D., Pietsch, M., Nagar, C., Fadli, Z., Huang, H., Tu, Y.-C., & Cheng, F. (2015) · Scientific Reports · doi:10.1038/srep17357 · Cited by 32
Drug combinatorics and side effect estimation on the signed human drug-target network
Torres, N. B., & Altafini, C. (2016) · BMC Systems Biology · doi:10.1186/s12918-016-0326-8 · Cited by 31
“Methods to predict in a systematic way such off-target interactions have attracted a considerable attention in recent years [17, 30–33].”
BackgroundChemical-protein interactome and its application in off-target identification
Yang, L., Wang, K., Wang, L., Jegga, A. G., Qin, S., He, G., Chen, J., Xiao, Y., & He, L. (2011) · Interdisciplinary Sciences Computational Life Sciences · doi:10.1007/s12539-011-0051-8 · Cited by 27
Li, S., & Xiao, W. (2025) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(25)60802-8 · Cited by 46
GESSE: Predicting Drug Side Effects from Drug–Target Relationships
Pérez‐Nueno, V. I., Souchet, M., Karaboga, A. S., & Ritchie, D. W. (2015) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5b00120 · Cited by 27
Budak, C., Mençik, V., & Gider, V. (2021) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2021.2010601 · Cited by 26
“…extensive application in various fields such as drug repositioning (Bibi et al., 2021), drug-drug interaction prediction (Ferdousi et al., 2017), drug target identification (Campillos et al., 2008), and drug side-effects prediction (Lounkine et al., 2012), can be calculated from different sources.”
BackgroundAI-powered drug repurposing for developing COVID-19 treatments
Liu, Z., Chen, X., Carter, W., Moruf, A., Komatsu, T. E., Pahwa, S., Chan‐Tack, K. M., Snyder, K., Petrick, N., Cha, K., et al. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824010-6.00005-8 · Cited by 39
El-Maadawy, W. H., Hassan, M., Badawy, M. H., AbuSeada, A., & Hafiz, E. O. A. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120933 · Cited by 27
Liu, B.-M., Gao, Y.-L., Zhang, D.-J., Zhou, F., Wang, J., Zheng, C.-H., & Liu, J. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbac457 · Cited by 26
Recent Trends in Computer-aided Drug Design for Anti-cancer Drug Discovery
Razia, I. T., Kanwal, A., Riaz, H. F., Malik, A., Ahsan, M., Khan, M. S., Raza, A., Sabir, S., Sajid, Z., Khan, M. F., et al. (2023) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266258467231107102643 · Cited by 30
Data mining methodologies for pharmacovigilance
Liu, M., Matheny, M. E., Hu, Y. Q., & Xu, H. (2012) · ACM SIGKDD Explorations Newsletter · doi:10.1145/2408736.2408742 · Cited by 28
“[15] where they extrapolated new drug targets by analyzing the likelihood of sharing protein targets for 277,885 pairs of 746 marketed drugs using their side-effect similarities.”
Vogt, I., Prinz, J., & Campillos, M. (2014) · Genome Medicine · doi:10.1186/s13073-014-0052-z · Cited by 28
“The semantic similarity measurement has been adapted from the method introduced by Resnik [45] combined with a weighting scheme to downweight frequent and correlated terms [8] (see Methods for details).”
BackgroundMethodInfluentialSelf-citationShin, E.-J., Lee, Y. C., Kim, S. R., Kim, S. H., & Park, J. (2015) · Scientific Reports · doi:10.1038/srep17784 · Cited by 26
“In the disease-based approach, a molecular network of disease and/or side effect similarities can guide the discovery of a new indication of the existing drugs 6,7 .”
COLLECTIVE PAIRWISE CLASSIFICATION FOR MULTI-WAY ANALYSIS OF DISEASE AND DRUG DATA
Žitnik, M., & Zupan, B. (2015) · Pacific Symposium on Biocomputing (PSB) · doi:10.1142/9789814749411_0008 · Cited by 26
Novel approaches to map small molecule–target interactions
Kapoor, S., Waldmann, H., & Ziegler, S. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.05.020 · Cited by 35
Context-sensitive network-based disease genetics prediction and its implications in drug discovery
Chen, Y., & Xu, R. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw737 · Cited by 27
Rare Diseases: Drug Discovery and Informatics Resource
Zhao, M., & Wei, D. (2017) · Interdisciplinary Sciences Computational Life Sciences · doi:10.1007/s12539-017-0270-3 · Cited by 27
“constructed a network of 746 marketed drugs by phenotypic side-effect similarity, repositioned the drug–target association, and verified some of the predicted results [93].”
ResultDrug–target prediction utilizing heterogeneous bio-linked network embeddings
Zong, N., Wong, R. S. N., Yu, Y., Wen, A., Huang, M. S., & Li, N. (2019) · Briefings in Bioinformatics · doi:10.1093/bib/bbz147 · Cited by 32
Chrétien, B., Jourdan, J., Davis, A., Fédrizzi, S., Bureau, R., Sassier, M., Rochais, C., Alexandre, J., Lelong‐Boulouard, V., Dolladille, C., et al. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14690 · Cited by 26
Link Prediction via Graph Attention NetworkPreprint
Gu, W., Gao, F., Lou, X., & Zhang, J. (2019) · arXiv (Cornell University) · doi:10.48550/arxiv.1910.04807 · Cited by 26
Stratification of risk for hospital admissions for injury related to fall: cohort study
Castro, V. M., McCoy, T. H., Cagan, A., Rosenfield, H. R., Murphy, S. N., Churchill, S. E., Kohane, I. S., & Perlis, R. H. (2014) · BMJ · doi:10.1136/bmj.g5863 · Cited by 26
Drug Repositioning for P-Glycoprotein Mediated Co-Expression Networks in Colorectal Cancer
Beklen, H., Gülfidan, G., Arğa, K. Y., Mardinoğlu, A., & Turanlı, B. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01273 · Cited by 28
“Signature-Based Drug Repositioning Drug repositioning analysis was performed by targeting genes within the co-expression networks via L1000CDS2 (24) search tool including the Library of Integrated Network-based Cellular Signatures (LINCS) L1000 data (25) by using the knowledge about downregulation and upregulation of…”
MethodKaitoh, K., & Yamanishi, Y. (2021) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.1c00967 · Cited by 33
Repurposing – second life for drugs
Ayyar, P., & Subramanian, U. (2022) · Pharmacia · doi:10.3897/pharmacia.69.e72548 · Cited by 27
“3C) (Campillos et al. 2008).”
Ha, J., Kim, H., Yoon, Y., & Park, S. (2015) · Bio-Medical Materials and Engineering · doi:10.3233/bme-151477 · Cited by 25
“Moreover, the analysis of interactions between drugs and genetic factors blazed a trail for discerning new indications of approved drugs [22, 23].”
Integrated Analysis of Drug-Induced Gene Expression Profiles Predicts Novel hERG Inhibitors
Babcock, J. J., Du, F., Xu, K., Wheelan, S. J., & Li, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0069513 · Cited by 28
Perez-Lopez, Á. R., Szalay, K. Z., Türei, D., Módos, D., Lenti, K., Korcsmáros, T., & Csermely, P. (2015) · Scientific Reports · doi:10.1038/srep10182 · Cited by 25
Medication-indication knowledge bases: a systematic review and critical appraisal
Salmasian, H., Tran, T. H., Chase, H. S., & Friedman, C. (2015) · Journal of the American Medical Informatics Association · doi:10.1093/jamia/ocv129 · Cited by 27
Off-Target Networks Derived from Ligand Set Similarity
Keiser, M. J., & Hert, J. (2009) · Methods in molecular biology · doi:10.1007/978-1-60761-274-2_8 · Cited by 28
A Flexible and Robust Multi-Source Learning Algorithm for Drug Repositioning
Chen, H., & Li, J. (2017) · ACM International Conference on Bioinformatics, Computational Biology, and Health Informatics (ACM-BCB) · doi:10.1145/3107411.3107473 · Cited by 27
Drug-induced diabetes type 2: In silico study involving class B GPCRs
Latek, D., Rutkowska, E. E., Niewieczerzał, S., & Cielecka‐Piontek, J. (2019) · PLoS ONE · doi:10.1371/journal.pone.0208892 · Cited by 28
Predicting Drug Interaction With Adenosine Receptors Using Machine Learning and SMOTE Techniques
Saad, A. I., Omar, Y. M. K., & Maghraby, F. A. (2019) · IEEE Access · doi:10.1109/access.2019.2946314 · Cited by 25
“[13] predicted targets (proteins) using side-effect similarity.”
In Silico ADME/Tox Predictions
Lagorce, D., Reynès, C., Camproux, A., Miteva, M. A., Spérandio, O., & Villoutreix, B. O. (2010) · Wiley eBooks · doi:10.1002/9780470915110.ch2 · Cited by 29
The impact of AI on modern oncology from early detection to personalized cancer treatment
Li, J., Zhang, L., Yu, Z., Bao, Z., Li, D., & Wang, L. (2026) · npj Precision Oncology · doi:10.1038/s41698-026-01276-6 · Cited by 24
Using quantitative systems pharmacology for novel drug discovery
Pérez‐Nueno, V. I. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.1082543 · Cited by 25
“Considerable effort is now being put into the computational [20-22] and experimental [23,24] screening of several suspected off-target proteins in the hope that side effects might be identified early, before the cost associated with developing a drug candidate rises steeply [25,26].”
BackgroundMethodSmall-molecule binding sites to explore protein–protein interactions in the cancer proteome
Xu, D. D., Jalal, S. I., Sledge, G. W., & Meroueh, S. O. (2016) · Molecular BioSystems · doi:10.1039/c6mb00231e · Cited by 24
Bajorath, J. (2008) · Expert Opinion on Drug Discovery · doi:10.1517/17460440802536496 · Cited by 29
“The exploration of pharmacological space is closely linked to the design of network representations that explicitly or implicitly capture drug–target interactions [9-14] .”
BackgroundSoldatos, T. G., Kim, S., Schmidt, S., Lesko, L. J., & Jackson, D. (2022) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12765 · Cited by 27
GES Polypharmacology Fingerprints: A Novel Approach for Drug Repositioning
Pérez‐Nueno, V. I., Karaboga, A. S., Souchet, M., & Ritchie, D. W. (2014) · Journal of Chemical Information and Modeling · doi:10.1021/ci4006723 · Cited by 24
Metadata
- Authors
- Campillos, M., Kuhn, M., Gavin, A.-C., Jensen, L. J., & Bork, P.
- Affiliations
- European Molecular Biology Laboratory (EMBL), Meyerhofstrasse 1, 69117 Heidelberg, Germany.
- Max Delbrück Center (DE)
- Corresponding author
- Kuhn, Michael
- Venue
- Science
- Published
- 2008-07-11
- Volume
- 321
- Issue
- 5886
- Pages
- 263-266
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2154896031
- Cited by
- 1,248
- References
- 27
- Citations by year
- 2026: 21 · 2025: 28 · 2024: 42 · 2023: 35 · 2022: 70 · 2021: 64 · 2020: 73 · 2019: 91 · 2018: 81 · 2017: 67 · 2016: 93 · 2015: 102 · 2014: 92 · 2013: 95 · 2012: 105
- FWCI
- 82.73
- Type
- journal article
- Language
- en
- Open access
- Licence
- cc-by
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bioinformatics and Genomic Networks
- Health Sciences › Medicine › Health Informatics › Biomedical Text Mining and Ontologies
- Keywords
- drug target identification, adverse drug reactions, phenotypic similarity, drug repurposing, drug-target interactions, marketed drugs
- MeSH terms
- Algorithms, Chemistry, Pharmaceutical, Drug Labeling, Drug Evaluation, Preclinical, Drug Therapy, Pharmaceutical Preparations, Humans, Probability, Proteins, Databases, Factual, Adverse Drug Reaction Reporting Systems, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.